EarlyDx-Cloud
A “One-Stop Shop” bioinformatics solution for liquid biopsy.
Technologies
EarlyDx-Cloud
Liquid biopsy will transform cancer care. However, a major barrier preventing many diagnostic companies from entering the liquid biopsy market is the lack of a bioinformatics team. We address this need by providing the EarlyDx-Cloud, a cloud platform that offers a “One-Stop Shop” bioinformatics solution for liquid biopsy. EarlyDx-Cloud is built using techniques in machine learning, probabilistic inference, and parallel algorithms, specifically developed for liquid biopsy and validated with patient data. Our platform is supported by our years of experience and publications.
EarlyDx-Cloud, in addition to commercially available gene panels, will allow many diagnostic companies to offer liquid biopsy clinical testing in cancer detection, therapy selection, and treatment monitoring. We aim to maximize the information gain from NGS and clinical data and turn liquid biopsy data into medical decisions.
